3/29
08:16 am
clrb
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven? [Yahoo! Finance]
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven? [Yahoo! Finance]
3/28
11:03 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
3/28
10:46 am
clrb
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/28
08:06 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
3/27
06:43 am
clrb
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update [Yahoo! Finance]
3/27
06:40 am
clrb
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Medium
Report
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
3/20
06:49 am
clrb
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 [Yahoo! Finance]
Low
Report
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 [Yahoo! Finance]
3/20
06:40 am
clrb
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Low
Report
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
3/14
08:52 am
clrb
Cellectar Biosciences to Present at the 36th Annual Roth Conference
Medium
Report
Cellectar Biosciences to Present at the 36th Annual Roth Conference
3/4
01:11 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $20.00 price target on the stock.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $20.00 price target on the stock.
3/4
06:51 am
clrb
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer [Yahoo! Finance]
Low
Report
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer [Yahoo! Finance]
3/4
06:40 am
clrb
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Low
Report
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
2/12
01:42 am
clrb
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss [Seeking Alpha]
Low
Report
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss [Seeking Alpha]
2/9
09:31 am
clrb
Thinking about buying stock in TOP Financial Group, Macy's, MicroCloud Hologram, Cellectar Biosciences, or New York Community Bancorp?
Low
Report
Thinking about buying stock in TOP Financial Group, Macy's, MicroCloud Hologram, Cellectar Biosciences, or New York Community Bancorp?
2/7
09:31 am
clrb
Thinking about buying stock in Cellectar Biosciences, elf Beauty, Glatfelter, Solidion Technology, or Spectral AI?
Low
Report
Thinking about buying stock in Cellectar Biosciences, elf Beauty, Glatfelter, Solidion Technology, or Spectral AI?
2/7
06:46 am
clrb
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/7
06:40 am
clrb
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
1/30
06:53 am
clrb
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study [Yahoo! Finance]
Medium
Report
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study [Yahoo! Finance]
1/30
06:40 am
clrb
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Medium
Report
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
1/25
09:31 am
clrb
Thinking about buying stock in Petros Pharmaceuticals, Xpeng Inc, Nukkleus, Cellectar Biosciences, or bluebird bio?
Medium
Report
Thinking about buying stock in Petros Pharmaceuticals, Xpeng Inc, Nukkleus, Cellectar Biosciences, or bluebird bio?
1/25
06:48 am
clrb
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million [Yahoo! Finance]
Medium
Report
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million [Yahoo! Finance]
1/25
06:40 am
clrb
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
Medium
Report
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million